Stocktoria
20/20 Biolabs, Inc. AIDX
Nasdaq · XNAS · stock · Services-Testing Laboratories · website · IPO 2021-09-08
20/20 Biolabs, Inc. statistics & valuation
Key ratios (by fiscal year)
| Ratio | FY2025 | FY2024 |
|---|---|---|
| Gross margin | 29.6% | 20.6% |
| Operating margin | -162.9% | -324.0% |
| Net margin | -182.8% | -316.8% |
| Return on assets | -90.4% | -154.9% |
| Return on equity | 19447.7% | -368.8% |
| Current ratio | 0.60 | 1.50 |
| Revenue growth | 16.7% | — |
Source: SEC EDGAR filings · CIK 0001139685 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.